 NEW YORK, April 16, 2021 PRNewswire -- AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop. 